Physician profile
William Tung
NPI 1154345205
$21,840.40
in general payments reported to CMS, 2019-2025
60 companies · $3,029 in 2025
The $3,029 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,905 · 2020: $1,849 · 2021: $3,940 · 2022: $3,660 · 2023: $3,237 · 2024: $4,221 · 2025: $3,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,335.26 |
| Education | $152.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,122.05 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $1,648.64 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,530.16 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,208.51 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $1,017.40 | 2019-2025 | Vyepti |
| Emd Serono, INC. | $992.48 | 2019-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $967.68 | 2023-2025 | |
| Sk Life Science, INC. | $824.17 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $789.12 | 2021 | |
| Eisai INC. | $787.73 | 2020-2025 | |
| Lilly USA, LLC | $682.92 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $675.68 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Biohaven Pharmaceutical Holding Company LTD. | $602.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $463.16 | 2021-2023 | Farxiga |
| Neurocrine Biosciences, INC. | $458.36 | 2024-2025 | Ingrezza |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $450.95 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $446.95 | 2020-2024 | Onzetra Xsail |
| Supernus Pharmaceuticals, INC. | $433.12 | 2019-2022 | |
| Genzyme Corporation | $420.33 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $411.85 | 2019-2025 | Ultomiris |
| Amgen INC. | $409.00 | 2019-2025 | Uplizna |
| Harmony Biosciences LLC | $396.55 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $393.53 | 2019-2025 | Epidiolex |
| Greenwich Biosciences, INC. | $275.26 | 2019 | |
| Neurelis, INC. | $235.10 | 2020-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $214.25 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $205.67 | 2023-2024 | Aptiom |
| Mdd US Operations, LLC | $198.71 | 2019-2023 | Gocovri |
| Allergan, INC. | $186.90 | 2020 | |
| Scilex Pharmaceuticals INC. | $169.38 | 2023-2025 | Ztlido |
| Kyowa Kirin, INC. | $159.59 | 2019-2022 | |
| Axsome Therapeutics, INC. | $156.62 | 2022-2025 | Symbravo |
| Celgene Corporation | $147.57 | 2021-2025 | Zeposia |
| Vertical Pharmaceuticals, LLC | $132.98 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $123.00 | 2020-2021 | |
| Boston Scientific Corporation | $120.36 | 2021 | |
| Impel Pharmaceuticals INC. | $114.92 | 2022 | |
| Abbott Laboratories | $110.59 | 2021-2025 | Infinity |
| Csl Behring | $104.75 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $94.08 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $91.23 | 2022-2024 | Quviviq |
| Forte Bio-Pharma LLC | $86.62 | 2025 | Tanlor |
| Amneal Pharmaceuticals LLC | $82.75 | 2019-2023 | Lyvispah |
| Acadia Pharmaceuticals INC | $70.16 | 2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $68.80 | 2024-2025 | Hyqvia |
| Argenx US, INC. | $68.20 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Banner Life Sciences, LLC | $64.28 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $59.61 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $52.78 | 2024-2025 | Ponvory |
| Azurity Pharmaceuticals, INC. | $52.34 | 2024-2025 | Horizant |
| Arbor Pharmaceuticals, INC. | $45.61 | 2019-2020 | |
| Ge Healthcare | $34.49 | 2025 | |
| Olympus America INC. | $32.63 | 2024 | Evis Exera III Colonovideoscope |
| Janssen Biotech, INC. | $28.13 | 2025 | Tremfya |
| Corium, LLC | $26.97 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.74 | 2025 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $21.64 | 2025 | |
| Merck Sharp & Dohme LLC | $21.52 | 2023 | Belsomra |
| Grifols USA, LLC | $13.15 | 2022 | |
| Zogenix INC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.